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Abstract: Thyroid disorders are highly prevalent, occurring most frequently in aging women. 
Thyroid-associated symptoms are very similar to symptoms of the aging process; thus, improved 
methods for diagnosing overt and subclinical hypothyroidism in elderly people are crucial. 
  Thyrotropin measurement is considered to be the main test for detecting hypothyroidism. 
  Combined evaluations of thyroid stimulating hormone (TSH) and free-thyroxine can detect 
overt hypothyroidism (high TSH with low free-thyroxine levels) and subclinical hypothyroidism 
(high TSH with normal free-thyroxine levels). It is difficult to confirm the diagnosis of thyroid 
diseases based only on symptoms, but presence of symptoms could be an indicator of who should 
be evaluated for thyroid function. The most important reasons to treat overt hypothyroidism are 
to relieve symptoms and avoid progression to myxedema. Overt hypothyroidism is classically 
treated using L-thyroxine; elderly patients require a low initial dose that is increased every 4 to 
6 weeks until normalization of TSH levels. After stabilization, TSH levels are monitored yearly. 
There is no doubt about the indication for treatment of overt hypothyroidism, but indications for 
treatment of subclinical disease are controversial. Although treatment of subclinical hypothy-
roidism may result in lipid profile improvement, there is no evidence that this improvement is 
associated with decreased cardiovascular or all-cause mortality in elderly patients. In patients 
with a high risk of progression from subclinical to overt disease, close monitoring of thyroid 
function could be the best option.
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Introduction
Thyroid disorders are highly prevalent, most frequently afflicting aging women.1 It 
is crucial to advance the means of diagnosing thyroid diseases, especially overt and 
subclinical hypothyroidism in elderly people, because thyroid-associated symptoms 
are very similar to symptoms of the normal aging process.2,3
Up till the early 1980s, laboratory diagnosis of thyroid dysfunction was made 
using radioimmunoassay for thyroid stimulating hormone (TSH); however, this 
method did not detect decreased TSH values, and is not a good test for the diagnosis 
of   hyperthyroidism. After the 1980s, immunometric assays for TSH emerged as the 
most cost-effective test for thyroid disease screening.4,5 The second-generation immu-
noassays can detect TSH values of 0.1 mIU/L and the third-generation assays are able 
to detect TSH values of 0.01 mIU/L.
Thyroid gland hormone production is directly stimulated by TSH, which 
is synthesized and secreted in the anterior pituitary under stimulation of 
  thyrotropin-releasing hormone produced in the hypothalamus. In patients with an intact 
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  hypothalamic-  pituitary-thyroid axis, a negative feedback 
regulatory mechanism controls thyroid gland metabolism. 
The pituitary serves as a biosensor of thyroid hormone 
  levels and regulates TSH levels according to the feedback 
of free-thyroxine (FT4) and free-triiodothyronine (FT3) 
levels. Decreases in thyroid hormone production stimulate 
more TSH secretion. The control system has a relatively 
slow response time and during periods of non-equilibrium, 
as occurs in the beginning of hypothyroidism, it is possible to 
find some discordance between the plasma thyroid hormone 
concentrations and the levels of TSH.
TSH measurement is considered to be the main test for 
detecting thyroid disease, specifically overt and subclinical 
hypothyroidism, for three main reasons. Firstly, there is an 
inverse log-linear relationship between the concentrations of 
TSH and FT4. Consequently, small linear reductions in FT4 
concentrations are associated with an exponential increase in 
TSH concentrations. Secondly, most cases of hypothyroidism 
in clinical practice are due to primary disease of the thyroid 
gland. Thirdly, immunometric assays for TSH present greater 
than 99% sensitivity and specificity.4,5
The second step in the screening of thyroid disorders 
is to determine the FT4 level. FT4 measurement is highly 
cost-effective compared to previously used measurements of 
total T4 or triiodothyronine. The combined measurements 
of TSH and FT4 can detect two types of hypothyroidism: 
overt and subclinical.
Overt hypothyroidism is defined as a combination of 
high TSH with low FT4, while subclinical hypothyroidism 
is defined as a combination of high TSH with normal FT4 
levels. There is some controversy regarding the presenta-
tion of subclinical hypothyroidism; some guidelines define 
it as a situation in which the patient is asymptomatic, while 
others state that subclinical hypothyroidism might include a 
few symptoms, but without any specific information about 
what symptoms can be involved.5,6 Data from some   studies 
have shown a positive relationship between increased 
TSH levels and the presence of antithyroid peroxidase 
antibodies.2,7 As subclinical hypothyroidism is defined by 
“high TSH with normal FT4,” the exact normal range of TSH 
is very important. The TSH range must be assessed in people 
with no evidence of disease – without positive antibodies in 
the serum and with no alteration detected upon ultrasono-
graphic examination.8 Another important point is that there is 
an individual hypothalamic-pituitary-thyroid axis set-point9 
that is genetically determined;10 differences in the individual 
set-point could explain the spectra of different symptoms 
presented in subjects with similar TSH values.8
This is a selective review that primarily includes data 
about thyroid diseases in elderly men and women.   However, 
several studies have included subjects aged 40 years or 
more and it is difficult to separate younger subjects from 
the older ones; therefore, some of the included data concern 
people of $40 years old or at least a sample with a mean 
age $40 years.
Epidemiology of thyroid diseases
Epidemiological studies have revealed that several changes 
in thyroid hormone concentrations occur with aging. The 
Whickham Survey undertaken in Britain provided data show-
ing that TSH levels did not vary with age among males, but 
increased markedly among females after the age of 45 years. 
Furthermore, this rise in TSH with age among women was 
virtually abolished when persons with antithyroid   antibodies 
were excluded from the sample.1 Data from the National 
Health and Nutrition Survey (NHANES III) confirmed that 
both TSH levels and the presence of antithyroid antibod-
ies are greater in women, increase with age, and are more   
common in whites than in blacks.11
The Framingham study evaluated an unselected popu-
lation of elderly subjects (.60 years) and found a 4.4% 
prevalence of thyroid deficiency, as evidenced by a clearly 
elevated serum thyrotropin level greater than 10 µIU/mL. 
Women exhibited thyroid deficiency (5.9%) more often 
than men (2.3%). The level of serum thyroxine (T4) was 
not a sensitive measure of thyroid deficiency. Of those 
with clearly elevated serum TSH levels, only 39% had 
low serum T4 levels; the remainder had serum T4 levels 
in the lower half of the normal range. An elevated serum 
TSH level has been noted as a sensitive marker of thyroid 
deficiency in the elderly, and is often the only way to 
detect it.12
More recently, data from several studies in healthy indi-
viduals without thyroid diseases have indicated that aging 
appears to be associated with decreased concentrations of 
TSH in healthy elderly humans, especially after inclusion 
of centenarians in the sample.13 This decrease could be 
attributed to an increased sensitivity to physiological nega-
tive feedback by thyroxin.14 The low serum concentrations 
of TSH result in clear, age-dependent declines in serum total 
and FT3 levels, whereas the reduction of both T4 secretion 
and peripheral T4 degradation of thyroxine results in no 
change in serum total and FT4 concentrations.14,15 In contrast, 
serum reverse-triiodothyronine, an inactivate metabolite of 
T4, seems to increase with age, especially in individuals with 
other chronic diseases.16
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For a physician to correctly interpret a high TSH level 
in terms of a hypothyroidism diagnosis, the positive and 
negative predictive values must be known; these depend on 
the prevalence of the disease in the general population. As a 
general rule, higher hypothyroidism prevalence in a popula-
tion sample indicates a higher positive predictive value of 
an increased TSH level for hypothyroidism diagnosis. So, 
in a population with a high prevalence of thyroid disease, 
the finding of an isolated increased TSH value should be 
sufficient to confirm the diagnosis.
A review published by the American College of 
  Physicians in 1998 estimated that population studies 
showed a pooled prevalence of overt hypothyroidism of 2% 
in women $70 years, and of 0.1% for men $60 years.17,18 
Table 1 shows the results of recent surveys for prevalence 
of overt and subclinical hypothyroidism in older subjects. 
We included only studies that used similar   methodology – 
high sensitive TSH and FT4 – to evaluate thyroid function. 
Most studies showed prevalence of between 1% to 10% 
of overt hypothyroidism, and of 1% to 15% of subclinical 
hypothyroidism, considering both genders. Frequencies 
of overt and subclinical hypothyroidism vary among the 
studies. Such variations could be associated with   several 
local factors, including differences in iodine intake 
among populations, differences in cut-off values used for 
  thyrotropin and FT4 levels and strategies of sample selec-
tion among studies.
Table 2 shows the results of two studies that evaluated the 
incidence of thyroid diseases in older people. Twenty years 
after the Whickham Survey, a follow-up of the cohort 
estimated the incidence and natural progression of thyroid 
disease. Of the 1877 surviving subjects, 91% were tested for 
clinical, biochemical, and immunological evidence of thyroid 
dysfunction.2 Among people with raised TSH levels alone at 
baseline, the odds ratio (OR) of having developed hypothy-
roidism at follow-up was eight (95% Confidence Interval 
[CI], 3 to 20) for women and 44 (95% CI, 19 to 104) for 
men. Among people with positive thyroid antibodies alone, 
the OR of having developed hypothyroidism at follow-up 
was eight (95% CI, 5 to 15) for women and 25 (95% CI, 10 
to 63) for men. The ORs among people with both conditions 
were 38 (95% CI, 22 to 65) for women and 173 (95% CI, 81 
to 370) for men. In women, neither a positive family history 
nor parity showed an association with future development 
of hypothyroidism.2 Gopinath et al showed that the 5-year 
incidence of hypothyroidism in the older population was 
relatively low, and was associated with obesity (body mass 
index $30 kg/m2) and serum TSH levels .2 mIU/L.25
Table 1 Prevalence of overt and subclinical hypothyroidism in elderly people
Reference Place Sample Age of participants Measurementsa Prevalence (%)
Flatau et al19 
cross-sectional
Israel 
Kibbutz members
751 (289 men  
and 462 men)
$65 years 
Range: 65–92 years
TSH (.4.5 mIU/L),  
FT4 (14 to 28 pmol/L)
Overt and subclinical  
in men: 9.7% 
Overt and subclinical  
in women: 18.2% 
38% of all hypothyroid  
subjects presented  
subclinical  
hypothyroidism
Cappola et al20 
cohort study
US, community  
dwelling individuals
3233 (1307 men  
and 1926 women)
$65 years TSH (.4.5 mIU/L),  
FT4 (not informed)
Overt: 1.6% 
Subclinical: 15.0%
Gussekloo et al21 
cohort study
The Netherlands,  
population based
558 (189 men  
and 369 women)
$85 years TSH (.4.8 mIU/L)  
FT4 (,13 pmol/L)
Overt: 7.0% 
Subclinical: 5.0%
wilson et al22 
cross-sectional
United Kingdom,  
community sample 
registered with  
20 family practices
5960 (2892 men  
and 2980 women)
$65 years TSH (.5.5 mIU/L),  
FT4 (,9 pmol/L),  
FT3 (,3.5 pmol/L)
Overt: 0.4% (men 0.4% 
and women 0.4%) 
Subclinical: 2.9% (men 
2.0% and women 3.7%)
Diaz-Olmos et al23 Brazil, women  
at workplace
314 $40 years 
Mean age: 47.6 years
TSH (.4.0 mIU/L),  
FT4 (,10 pmol/L)
Overt: 3.5% 
Subclinical: 7.3%
Bensenor et al24 
cross-sectional
Brazil 
population-based
1373 (538 men  
and 835 women)
$65 years-old TSH (.5.0 mIU/L),  
FT4 (,10 pmol/L)
Overt 
Men: 5.4% 
women: 5.9% 
Subclinical 
Men: 6.1% 
women: 6.7%
Abbreviations: TSH, thyrotropin or thyroid stimulating hormone; FT4, free-thyroxine; FT3, free-triiodothyronine.
Note: aMeasurements (cut-off points for diagnosis of overt hypothyroidism).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
99
Hypothyroidism in the elderlyClinical Interventions in Aging 2012:7
Diagnosis of hypothyroidism  
in elderly people
Diagnosis of hypothyroidism is not easy because most of the 
symptoms, especially in mild cases, are nonspecific and are 
frequently attributed to other causes or to the aging process 
itself. This is especially a problem in older patients because 
symptoms such as fatigue, lack of concentration, dry skin, 
and many others are considered – correctly or not – to be 
normal parts of the aging process. Three different clinical 
conditions – hypothyroidism, depression, and presence of 
anemia – share common and nonspecific symptoms and 
are each common conditions in older people. The fre-
quency of anemia, defined according to the World Health 
Organization, is higher than 10% in community-dwelling 
adults aged 65 years and older, and is frequently associated 
with other clinical conditions.26,27 Depressive symptoms, or 
even depression, are common in elderly people, especially 
associated with other physical comorbidities.28,29 Within 
this setting, the differential diagnosis of these three condi-
tions is crucial.
It is impossible to confirm a diagnosis of hypothyroidism 
based on clinical symptoms alone, without TSH and FT4 
determinations. Due to the increased prevalence according to 
age and the impossibility of ruling out the diagnosis without 
laboratory measurements, several guidelines recommend 
routinely screening for thyroid diseases after a certain age.30 
The American Thyroid Association recommends screening 
both women and men at 35 years of age, and every 5 years 
thereafter.31 Also assertively in favor of screening, The 
American Association of Clinical Endocrinologists recom-
mends screening in older patients, especially for women,32 
and the American College of Pathologists recommends 
evaluations for women aged over 50 years with one or more 
general symptoms that could be caused by thyroid disease.33 
The American Academy of Family Physicians recommends 
screening for patients over 60 years old, independent of 
gender,34 and the American College of Physicians recom-
mends high-risk strategy for people aged over 50 years 
with nonspecific complaints.17,18 Among organizations that 
encourage screening, there is no agreement regarding the 
guidelines for age and sex.
In contrast, other institutions such as the US   Preventive 
Services Task Force,35 the Canadian Task Force on the 
P  eriodic Health Examination,36 and the British Royal 
  College of Physicians37 do not recommend screening for 
adults or for the elderly. The Institute of Medicine evaluated 
evidence for a benefit of screening for thyroid disorders 
in the Medicare population, but decided against screen-
ing based on a cost-effectiveness analysis.38 In 2004, an 
independent panel sponsored by three major professional 
societies – the American Thyroid Association, the American 
Association of Clinical Endocrinologists, and the Endocrine 
Society – recommended against screening;39 however, the 
three sponsoring societies did not endorse a statement in 
favor of screening.
Table 3 shows the results of studies that evaluated the 
diagnosis of unrecognized hypothyroidism in elderly people 
in different scenarios. The frequency of overt thyroid diseases 
without previous diagnosis is low, around 1% in men and 2% 
in women. In many cases, symptoms of hypothyroidism are 
insidious and may go unnoticed for months or even years, 
making medical diagnosis difficult.44 It is important to note 
that the diagnosis of overt thyroid disease now occurs earlier 
in the disease progression, so the comprehensive list of symp-
toms described in internal medicine books is almost never 
fully present. The only study that evaluated   unrecognized 
hypothyroidism diagnosis in an emergency department found 
a very small number of cases.43 However, it was a retrospec-
tive study using data from hospital admissions, with the 
typical limitations of this type of strategy.
Table 2 Incidence of overt hypothyroidism in elderly people
Reference Place Sample Age of participants Measurementsa Incidence (%)
vanderpump et al2,b 
cohort study
United Kingdom 1877, population 
based
$38 years TSH (not informed),  
FT4 (not informed)
Overt 
Men: 0.6/1000 survivors/year 
women: 3.5/1000 survivors/year
Gopinath et al25 
cohort study
Australia 951, population  
based
$55 years TSH (.4.0 mIU/L),  
FT4 (,11.5 pmol/L)
Overt 
Men: 1.4%/5 year 
women: 3.5%/5 year 
Subclinical 
Men: 0.7%/5 year 
women: 2.5%/5 year
Notes: aMeasurements (cut-off for diagnosis of overt hypothyroidism); bas there are few studies evaluating incidence of overt hypothyroidism in elderly people, this study 
was included; mean age was 58 years (range 38–93 years).
Abbreviations: TSH, thyrotropin or thyroid stimulating hormone; FT4, free-thyroxine.
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Table 3 Unrecognized cases of overt hypothyroidism in elderly people at different scenarios
Reference Place Sample Age of participants Measurements Frequency of unrecognized cases  
of overt hypothyroidism (%)
Primary care
Petersen et al40 
cross-sectional
Sweden 1154, population based $50 years TSH, FT4 women: 1.3%
Bemben et al 
(Part 1)41 
retrospective
US 283, retrospective analysis  
in a Department of Family 
Medicine
.60 years 
Range: 60–97 years
TSH, FT4 Men: 1.3% 
women: 1.0%
Bensenor et al24 
cross-sectional
Brazil 1373, population based $65 years TSH, FT4 Men: 4.8% 
women: 3.4%
Outpatient clinics
Nyström et al42 
cross-sectional
Sweden 496, users of an  
outpatient clinic
$50 years TSH, FT4 women: 2.2%
Ward
Nyström et al42 
cross-sectional
Sweden 383, inpatients of  
emergency ward
$50 years TSH, FT4 women: 1.3%
Emergency department
Chen et al43,a 
retrospective
Taiwan 54,756, hospital admissions  
at emergency department
Mean age:  
75.8 ± 12.8 
Range:  
27–98 years
TSH, FT4 Overt: 0.1% (men 0.06%, women: 0.04%) 
Myxedema: 0.01% 
Only 21% of patients were admitted 
from the emergency room with an 
initial impression of primary overt 
hypothyroidism
Note: aAs there are no studies evaluating unrecognized cases of overt hypothyroidism in emergency department only in samples of elderly people, this study (age range 27–98 years) 
was included; however mean age of subjects was 75.8 ± 12.8 years.
Abbreviations: TSH, thyrotropin or thyroid stimulating hormone; FT4, free-thyroxine.
Table 4 lists the most recent studies that have addressed 
the presence of symptoms in subjects with subclinical hypo-
thyroidism compared to controls. Most of these studies did 
not show differences in the presence of clinical symptoms, 
anxiety and depressive symptoms, or worse cognitive per-
formance in subjects with subclinical hypothyroidism com-
pared to controls with normal thyroid function in different 
scenarios. Although it is not often possible to confirm the 
diagnosis of thyroid diseases based only on symptoms, the 
presence of symptoms could be an indicator of who should 
be screened for thyroid function.51
Canaris et al evaluated the use of a positive likelihood 
ratio (LR) associated with several symptoms to identify 
hypothyroidism.44 They applied a questionnaire, asking about 
14 symptoms associated with hypothyroidism, in patients 
with and without overt hypothyroidism who were selected 
from the laboratory according to their levels of TSH and FT4. 
They also asked the patients to report if each of the symptoms 
had changed in the last year. Euthyroid subjects reported a 
mean of 16.5% and hypothyroid subjects reported 30.2% of 
listed symptoms (P , 0.0001). Symptoms that occurred more 
frequently in cases than controls were hoarse voice (17% 
versus 4%; positive LR, 4.2; 95% CI, 1.7–10.6), dry skin 
(71% versus 54%; positive LR, 1.3; 95% CI, 1.1–1.6), and 
muscle cramps (34% versus 15%; positive LR, 2.2; 95% CI, 
1.4–3.7). When asked if the symptoms had changed in the last 
year, increased frequency of symptoms was reported more 
often in hypothyroid subjects compared to controls, with 
13 symptoms presenting statistically significant   differences: 
hoarse voice, deeper voice, drier skin, colder, more tired, 
puffier eyes, more muscle cramps, weaker muscles, more 
constipated, more depressed, slower thinking, poorer memory, 
and more difficulty with math. For diagnosing hypothyroid-
ism, the LR was 0.5 for no reported symptoms compared to 
an LR of 8.7 (95% CI, 3.8–20.2) for the presence of seven 
or more symptoms.44 Using data from the literature to deter-
mine a pretest probability of hypothyroidism according to 
age and sex, this knowledge of the LR enables calculation 
of the post-test probability using the nomogram of Fagan, 
and to consequently “rule in” or “rule out” the diagnosis of 
hypothyroidism.52
Treatment of overt hypothyroidism
The most important reasons to treat overt hypothyroidism are 
the relief of symptoms and to avoid progression of disease 
to myxedema. In elderly people, low levels of TSH53 or high 
levels of FT4 that are still in the normal range are associated 
with higher mortality,3 but the same is not clear for high levels 
of TSH21 or low levels of FT4.3 Gussekloo et al evaluated 
a general population of people who were 85 years of age at 
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the beginning of the study;21 after a follow-up of 4 years, 
they concluded that elderly individuals with high TSH levels 
have a prolonged life span. The hazard ratio for mortality 
was 0.77 (95% CI, 0.63 to 0.94) for a standard deviation 
increase of 2.71 mIU/L of thyrotropin. Likewise, van den 
Beld et al showed that low serum FT4 levels are associated 
with a   longer 4-year survival, reflecting a possible adaptive 
mechanism to prevent excessive catabolism in the elderly.3
Overt hypothyroidism is classically treated by oral 
replacement with synthetic L-thyroxine. L-thyroxine is 
peripherally converted to FT3, the active form of thyroid 
hormone; it has a half-life of 6 days and is typically admin-
istered as a once-daily dose of 1.6 µg/kg.54 Although, some 
authors recommend to use an initial dose lower than the usual 
dose to treat overt hypothyroidism in elderly patients,8,54 
there is little evidence about this issue. A small study sug-
gested that elderly patients need a lower dose of L-thyroxine 
compared to younger patients.55 Contrasting, a recent clini-
cal trial concluded that a full starting dose of levothyroxine 
in asymptomatic patients (mean-age of 47 years, range 
of 25–86 years) is safe and may be more convenient and 
cost-effective than a low starting dose regimen. No patients 
were excluded from the analysis based on the presence of 
side effects of L-thyroxine. However, patients with previous 
history of coronary heart disease were excluded from the 
samples and most of them were elderly.56 A retrospective 
study evaluated L-thyroxine replacement doses and found 
no differences between younger and older patients regarding 
the L-thyroxine doses used.57 After stabilization, TSH levels 
can be monitored yearly. The most frequent complications 
of treatment in older people are myocardial ischemia and 
arrhythmias, especially atrial fibrillation, although these still 
occur at a low rate.8,13,58
Some researchers have evaluated whether a combination 
of T4 and triiodothyronine or even liothyronine could pro-
vide better treatment for patients with persistent symptoms 
following treatment with L-thyroxine alone. Liothyronine is 
another form of thyroid hormone; it reaches peak concentra-
tions at 2–4 hours after oral administration with a half-life 
of 1 day, and thus cannot be used as a once-daily dose.59 
Combined treatment using L-thyroxine and triiodothyronine 
produced some positive results related to cognition and 
sensation of well-being in small trials,60,61 but most results 
showed no improvement with combined treatment.62–64 
Clyde et al tested a combination of levothyroxine plus 
liothyronine in the treatment of overt hypothyroidism and 
showed no beneficial changes in body weight, serum lipid 
levels, hypothyroid symptoms, or standard measures of 
cognitive performance from the combination treatment 
compared to L-thyroxine alone.59 Walsh et al also evaluated 
a combined thyroxine/liothyronine therapy with similar 
results.65
In a double-blind, placebo-controlled, crossover trial of 
L-thyroxine, Pollock et al evaluated the effect of treatment in 
people who exhibited symptoms of hypothyroidism but had 
thyroid function tests within the reference range. The same 
protocol was used for patients and controls.66 L-thyroxine 
was no more effective than placebo in improving cogni-
tive function or psychological well-being in patients or 
controls.66
Treatment of subclinical 
hypothyroidism
The most important reasons to treat subclinical hypothyroid-
ism are to relieve symptoms, to avoid progression to overt 
disease, and to possibly prevent cardiovascular and all-cause 
mortality that may be associated with subclinical disease. 
Most patients diagnosed as having subclinical hypothyroid-
ism have a low risk of complications and it is possible that 
their being labeled as having a “disease” is more dangerous 
than the actual risk of possible problems.
Table 5 shows the results of several clinical trials that 
have evaluated the effects of L-thyroxine administration 
in elderly people with subclinical hypothyroidism. Most of 
these studies were performed in subjects aged $50 years, or 
at least with a great part of the sample being $45 years old. 
Several trials did not show improvement of clinical symp-
toms of hypothyroidism,45,67–69,76 while only one trial showed 
improvement in tiredness after treatment with L-thyroxine.72 
However, several trials showed some kind of improvement 
in cardiovascular risk factors related to lipid profile.69,71–74 
One trial that evaluated C-reactive protein did not find any 
improvement after treatment with L-thyroxine.70 Another 
trial verified an improvement in pulse-wave velocity after 
treatment with L-thyroxine.75
A second reason to treat subclinical hypothyroidism is to 
avoid progression to overt disease. The two most important 
characteristics suggesting a progression of subclinical hypo-
thyroidism to overt disease are high TSH levels, especially 
when .10 IU/L, and the presence of antithyroid peroxidase 
antibodies. Both measurements can be followed by periodic 
testing every year or every 6 months. Table 6 shows two 
studies that evaluated the risk of developing overt hypothy-
roidism in subjects who had baseline levels of high TSH, 
antithyroid antibodies, or both. The combination of high TSH 
with antithyroid peroxidase antibodies was associated with 
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a high increase in the risk of developing overt disease.2,76 In 
a prospective 5-year analysis of a cohort study, Gopinath 
et al evaluated the prognostic risk factors at baseline associ-
ated with forthcoming subclinical or overt hypothyroidism. 
Female sex and high TSH as continuous variables were 
associated with increased risk of subclinical hypothyroidism. 
Fasting blood glucose, total white cell count (as a continu-
ous variable), and obesity (body mass index $30 kg/m2) 
were associated with increased risk of progression to overt 
disease.25 Although progression to overt disease is higher 
in the presence of these risk factors, it is possible to closely 
monitor the progression of subclinical hypothyroidism to 
overt disease.
As subclinical hypothyroidism has been associated with 
a worse profile of cardiovascular risk factors such as lipid 
alterations, one possible complication of not treating subclini-
cal hypothyroidism could be an increased cardiovascular risk. 
Another possible risk is if hypothyroidism is associated with 
an increased all-cause mortality mediated by some unknown 
factors beyond the causal pathway of dyslipidemia-heart 
disease.
Table 7 shows a list of cohort studies that estimated the 
incidences of cardiovascular disease or fractures in subjects 
with subclinical hypothyroidism. Only one study found an 
increased risk of congestive heart failure of 2.58 (95% CI, 
1.19–5.60) in subjects with TSH between 7.0 mIU/L to 
9.9 mIU/L, and of 3.26 (95% CI, 1.37–7.77) in subjects with 
TSH $10.0 mIU/L.78 Another showed an increased risk of hip 
fracture, only in men, with a multivariable-adjusted hazard 
ratio of 2.31 (95% CI, 1.25–4.27).83 Regarding mortality, only 
one study found an increased risk of all-cause mortality;80 
another showed a higher risk of cardiovascular mortality 
associated with subclinical hypothyroidism.80 So, although 
subclinical hypothyroidism is associated with a higher fre-
quency of cardiovascular risk factors, most evidence indicates 
that the effect is not sufficient to increase cardiovascular 
mortality or all-cause mortality. There is insufficient evi-
dence that treatment of subclinical hypothyroidism could 
be associated with a decrease in all-cause or cardiovascular 
mortality in the elderly.
This was reinforced by the results of a meta-analysis that 
analyzed the influence of age on the relationship between 
subclinical hypothyroidism and ischemic heart disease. It 
included 15 studies with 2531 participants with subclinical 
hypothyroidism and 26,491 euthyroid individuals. Incidence 
and prevalence of ischemic heart disease were higher in 
subjects aged ,65 years with subclinical hypothyroidism, 
but not in studies that included subjects aged .65 years. 
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Cardiovascular and all-cause mortality were also elevated in 
subjects of ,65 years of age, but not in subjects aged .65 
years (OR, 1.37; 95% CI, 1.04–1.79 vs OR, 0.85; 95% CI, 
0.56–1.29) suggesting that increased vascular risk may only 
be present in subjects with subclinical hypothyroidism who 
are less than 65 years old.84
When subclinical hypothyroidism is treated, an initial 
L-thyroxine dose of 0.05 µg to 0.075 µg per day is sufficient 
to normalize thyroid function. Patients with cardiovascular 
disease should receive smaller doses of 0.0125 µg to 0.025 µg 
per day. Measurements of thyrotropin levels should be 
repeated 4 to 6 weeks after starting therapy.85
Potential bias in the treatment  
of hypothyroidism regarding age 
and sex
Several studies have discussed possible biases in overt 
hypothyroidism treatment. Gussekloo et al observed 
558 participants and found that 39 new cases of overt thyroid 
disease were not being treated 2 years after diagnosis because 
the primary care physicians did not start hormone reposition 
therapy for disorders identified by screening.21 These findings 
suggested the possibility that a diagnosis of hypothyroidism 
via screening could be a bias in hypothyroidism treatment; 
age could also be a bias in these cases if this was the real 
motivation behind the lack of treatment. Interestingly,   nothing 
happened to these untreated patients, possibly suggesting a 
protective effect of no treatment in overt hypothyroidism 
since the hazard ratio for mortality for standard deviation 
increase of 2.71 mIU/L thyrotropin was 0.77 (95% CI, 
0.63–0.94; P = 0.09). However, as stated by the authors, a 
well-designed randomized placebo-controlled clinical trial 
is required to answer this question.
In the two cohorts of the Cardiovascular Health Study 
(mean age of 73 years; range 65–100 years), Somwaru et al 
evaluated the use of thyroid hormones along time. Use of 
thyroid hormones was observed from 1989 to 2006 in the 
original cohort of 4737 participants, and from 1992 to 2006 in 
the new cohort of 643 predominantly African–American 
participants. At the beginning of the study, frequency of hor-
mone use was 8.9% (95% CI, 8.1–9.7).86 However, hormone 
use increased to 20% during the 16 years of follow-up, at a 
rate of approximately 1% per year. Predictors of the initia-
tion of hormone use during the 16-year follow-up period 
included being a white woman, being over 85 years old, 
being more educated, having a higher body mass index, and 
past history of coronary heart disease. The authors concluded 
that the differences in thyroid hormone use by sex and race 
corresponded to the reported demographic differences in TSH 
distributions, suggesting a minor role of biases in screening 
practices by sex and race.86 These results are similar to those 
of two other studies.87,88
In a sample of 1373 older people living in an economically 
deprived area, Bensenor et al found more frequent diagnosis 
of previous overt hypothyroidism in women compared to men 
(P = 0.006).24 The authors speculate that this could be because 
women seek medical treatment more frequently than men. 
There could also be some kind of gender bias, since thyroid 
diseases are more frequent in women compared to men and, 
consequently, physicians may screen thyroid function with 
higher frequency in elderly women than men.
Wilson et al reported evidence of an association 
between socioeconomic deprivation and subclinical thyroid 
  dysfunction.22 This association persisted after adjusting for 
the effects of age, gender, comorbidity, and current drug 
therapies, and thus could be another source of bias regarding 
clinical diagnosis of thyroid diseases.
Conclusion
Subclinical and overt hypothyroidism are common disorders 
in elderly people, especially women. There is no doubt about 
the indication for treatment of overt disease; however, the 
same is not true for subclinical disease. Some data indicates 
that treatment of subclinical disease results in lipid profile 
improvement, but there is no evidence that this improvement 
is associated with a decrease in cardiovascular or all-cause 
mortality in elderly patients. Close monitoring of thyroid 
function could be the best option for patients at high risk of 
progression from subclinical to overt disease.
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